Comments to FDA: CP Regarding OTC Heartburn Products

Herein, CHPA provides comments on Citizen Petition FDA-2017-P-27331 which requests the addition of a warning to labeling for all OTC drug products labeled to relieve or prevent heartburn associated with reflux disease, acid indigestion, and sour stomach noting that these products do not eliminate the risk of esophageal cancer.